Abstract
Background: Isolated limb perfusion (ILP) is a treatment option for patients with melanoma in-transit metastases of the extremities. ILP enables administration of very high doses of chemotherapeutics regionally with low systemic toxicity. We have shown that ILP causes an immunological activation with melanoma-specific CD8+ T-cells, however this effect is blocked, this partly being due to an up-regulation of PD-1 on the T-cells. The aim of this study is to evaluate the safety and efficacy of adding the PD-1 inhibitor nivolumab to ILP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
